Holen Sie sich die Stockscreener-App
52.88
2.24%
-1.21
Handel nachbörslich:
52.89
0.010
+0.02%
Schlusskurs vom Vortag:
$54.09
Offen:
$54.2
24-Stunden-Volumen:
1.80M
Relative Volume:
0.89
Marktkapitalisierung:
$10.22B
Einnahmen:
$3.24B
Nettoeinkommen (Verlust:
$348.90M
KGV:
29.68
EPS:
1.7817
Netto-Cashflow:
$717.02M
1W Leistung:
+6.16%
1M Leistung:
-0.56%
6M Leistung:
-4.76%
1J Leistung:
-8.11%
1-Tages-Spanne:
$52.76
$54.48
1-Wochen-Bereich:
$49.41
$55.05
52-Wochen-Spanne:
$49.26
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.88 | 10.45B | 3.24B | 348.90M | 717.02M | 1.7817 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Fortgesetzt | Morgan Stanley | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
8 New 5-Star Stocks This Week - Morningstar
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Navigating a Potential 62.41% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
BMRN stock down on mixed results from rare disease therapy study - MSN
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Understanding the Setup: (BMRN) and Scalable Risk - Stock Traders Daily
BMRN Maintains Rating by Canaccord Genuity -- Price Target Lowered to $111 - GuruFocus
Citigroup and I Are Aligned on These 3 Mid-Cap Biopharma Stocks - TheStreet Pro
H.C. Wainwright reiterates Neutral on BioMarin stock, $50 target By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral on BioMarin stock, $50 target - Investing.com
Layoff Tracker: AbbVie, Novartis slash US headcount - BioSpace
BioMarin (BMRN) EVP Cristin Hubbard reports 2,318-share tax-withholding disposition - Stock Titan
BioMarin Reveals Dwarfism Study Data, Stock SoarsBioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BioMarin Looks To Expand Voxzogo Franchise With Positive Hypochondroplasia Data - Citeline News & Insights
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid - Fierce Pharma
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint - Insider Monkey
BioMarin’s Voxzogo hits Phase III goal in hypochondroplasia - The Pharma Letter
BioMarin Pharmaceutical stock (US09061G1013): Voxzogo Phase 3 success sparks growth hopes - AD HOC NEWS
BioMarin moves to expand Voxzogo into hypochondroplasia with pivotal win - FirstWord Pharma
BioMarin Pharmaceutical (BMRN) 10K Form and Latest SEC Filings 2026 - MarketBeat
BioMarin’s Voxzogo meets primary endpoint in hypochondroplasia trial - Investing.com UK
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin’s Voxzogo meets primary endpoint in hypochondroplasia trial By Investing.com - Investing.com South Africa
BioMarin stock surges on positive hypochondroplasia trial data - Investing.com
BioMarin's drug shows significant growth gains in children in late-stage trial - marketscreener.com
BioMarin stock surges on positive hypochondroplasia trial data By Investing.com - Investing.com Nigeria
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia - PR Newswire
5 Best Low Priced Stocks to Buy for the Next 3 Years - Insider Monkey
BioMarin Trial Setback Puts Rare Disease Pipeline And Valuation In Focus - Sahm
BMRN Maintained by B of A Securities -- Price Target Lowered to $80 - GuruFocus
BMRN Initiates Coverage by Citigroup -- Price Target Announced a - GuruFocus
BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug - MedCity News
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - The Globe and Mail
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
BioMarin’s SWOT analysis: rare disease biotech stock faces competitive headwinds - Investing.com
BioMarin drug acquired in buyout misses goal in rare disease study - BioPharma Dive
H.C. Wainwright cuts BioMarin stock price target after trial miss - Investing.com India
BioMarin rare disease biologic meets only 1 of 2 endpoints in phase 3 trial - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth - ChartMill
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop - BioSpace
H.C. Wainwright cuts BioMarin stock price target after trial miss By Investing.com - Investing.com Canada
Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50 - TradingView
Citigroup initiates coverage of BioMarin Pharmaceutical (BMRN) with buy recommendation - MSN
BioMarin (BMRN) Faces Setback in ENPP1 Deficiency Drug Trial - GuruFocus
BMRN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):